Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 1 of 1
Full-Text Articles in COVID-19
Randomized, Double-Blind, Placebo-Controlled Clinical Trial To Assess The Safety And Effectiveness Of A Novel Dual-Action Oral Topical Formulation Against Upper Respiratory Infections, Pranab K. Mukherjee, Frank Esper, Ken Buchheit, Karen Arters, Ina Adkins, Mahmoud A. Ghannoum, Robert A. Salata
Randomized, Double-Blind, Placebo-Controlled Clinical Trial To Assess The Safety And Effectiveness Of A Novel Dual-Action Oral Topical Formulation Against Upper Respiratory Infections, Pranab K. Mukherjee, Frank Esper, Ken Buchheit, Karen Arters, Ina Adkins, Mahmoud A. Ghannoum, Robert A. Salata
Faculty Scholarship
BACKGROUND: Current prevention options for upper respiratory infections (URIs) are not optimal. We conducted a randomized, double-blinded, placebo-controlled pilot clinical trial to evaluate the safety and efficacy of ARMS-Iâ„¢ (currently marketed as Halo™) in the prevention of URIs. METHODS: ARMS-I is patented novel formulation for the prevention and treatment of influenza, comprising a broad-spectrum antimicrobial agent (cetylpyridinium chloride, CPC) and components (glycerin and xanthan gum) that form a barrier on the host mucosa, thus preventing viral contact and invasion. Healthy adults (18—45 years of age) were randomized into ARMS-I or placebo group (50 subjects each). The drug was sprayed intra-orally …